(355) Evaluation of Apisolex™ for Parenteral Use: Solubilizing Poorly Soluble Small Molecules and PROTACs
Introduction: Parenteral administration of poorly soluble small molecules and PROTACs) at reasonably high doses has been challenging due to poor solubility. Apisolex™ LY (Lubrizol) is a multiblock copolymer composed of poly(sarcosine) and D,L-mixed poly(amino acid) blocks. This copolymer has the potential to substantially increase the solubility of active pharmaceutical ingredients for parenteral applications. It is non-toxic, non-immunogenic, biocompatible, and biodegradable. We carefully selected five internal AZ model compounds with challenging properties and conducted a comprehensive evaluation.
Learning Objectives:
Upon completion, participant will be able to learn Apisolex for potential solubility enhancing.
Annette Bak, NA – Executive Director, AstraZeneca; Hsinchieh Chen, NA – Scientist, AstraZeneca; Paresh Chothe, NA – Associate Principal Scientist, AstraZeneca; Eric Gosselin, NA – Sr Scientist, AstraZeneca; Stacey Marden, NA – Associate Principal Scientist, AstraZeneca; Sanjib Saha, NA – Sr Scientist, AstraZeneca; Aixiang Xue, NA – Sr Scientist, AstraZeneca; Wenzhan Yang, NA – Principal Scientist, AstraZeneca; Liping Zhou, NA – Senior Director, AstraZeneca
